Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
New England Journal of Medicine · 27.11.2025 · 393 (21) · 2119-2130
DOI: 10.1056/nejmoa2511778 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 27.11.2025. Verfasst von Luke J Laffin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, CRISPR-Cas Systems, Dyslipidemias, Gene Editing. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: CRISPR Therapeutics AG.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland.
- Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
- Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
- New Zealand Clinical Research, Christchurch, New Zealand.
- Royal Adelaide Hospital, Adelaide, SA, Australia.
- Aotearoa Clinical Trials, Auckland, New Zealand.
ORCID-Profile: Ashish Sarraju, Steven E Nissen
Förderung
- CRISPR Therapeutics AG
Zitieren
APA
Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2025). Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. New England Journal of Medicine, 393(21), 2119-2130. https://doi.org/10.1056/nejmoa2511778
Vancouver
Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. New England Journal of Medicine. 2025;393(21):2119-2130. doi:10.1056/nejmoa2511778
BibTeX
@article{Laffin2025,
author = {Laffin, Luke J and Nicholls, Stephen J and Scott, Russell S and Clifton, Peter M and Baker, John and Sarraju, Ashish and Singh, Shweta and Wang, Qiuqing and Wolski, Kathy and Xu, Huansheng and Nielsen, Jen and Patel, Naimish and Duran, Jason M and Nissen, Steven E},
title = {Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {21},
pages = {2119--2130},
doi = {10.1056/nejmoa2511778}
}
EUVIMED